Insulin Market, 2012 to 2023
Insulin Market: Insulin is an anabolic hormone secreted by β-cells of pancreatic islets. Insulin helps in the metabolism of carbohydrates, proteins, and fats by absorbing the glucose and converts to glycogen by glycogenesis and stores in the skeletal muscles. Deficiency of insulin leads to the hyperglycemia or diabetes mellitus. Insulin is commonly used in type-1 diabetes, however, rarely used in the type 2 diabetes. The β-cells of the pancreas are destroyed due to the autoimmune reaction and causes insulin deficiency which leads to type-1 diabetes. In type 2 diabetes, the body becomes more resistant to insulin and requires more insulin for the carbohydrate metabolism.
Global Market Outline: Insulin Market
Increase in the prevalence of diabetes, technological advancements in the insulin administration devices such as pen devices, change in the lifestyle leads to early onset of diabetes, the rise in the incidence of obesity, and favourable reimbursement policies expected to boost the insulin market over the forecast period. Moreover, product approval for insulin biosimilars in January 2016 by FDA for the Basaglar biosimilar in U.S, increase the awareness about the insulin usage, ease of administration, availability of the wider products, an upsurge in the demand for insulin analogues are anticipated propel the market over the forecast period. However, stringent regulatory policies for product approval, a high cost of the insulin, and manufacturing complexities might hamper the growth of insulin market over the forecast timeframe.
Global insulin market is segmented on the product type, diabetes type, and end user
Based on the product type, insulin market is segmented into the following:
Ultra-short acting insulin
Short-acting insulin
Intermediate-acting insulin
Long-acting insulin
Premixed insulin
Based on the diabetes type, insulin market is segmented into the following:
Type 1 diabetes
Type 2 diabetes
Based on the end user, insulin market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global insulin market is in the developed stage with several players operating in the market. Increase in the prevalence of diabetes and obesity, increase in the R&D activities for the development of insulin such as oral insulin and insulin patches is anticipated to propel the insulin market in the forthcoming years. Acquisitions & mergers, collaborations, product approval and launchings, and patent filings for the devices are some key strategies followed by the companies. For instance, in February 2016, Eli Lilly and Co. acquired Glycostasis, Inc. for the development of insulin. In addition, in August 2016, Emperra has launched Bluetooth enabled the insulin-delivering device in Germany.
Geographically, the insulin market is segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America anticipated to healthy growth rate owing to increase in the prevalence of diabetes in the U.S. (According to American Diabetes Association, the prevalence of diabetes in 2015 is 30.3 Mn or 9.4% in U.S.), a rise in the healthcare expenditure, and technological advancements in insulin administration. Europe holds a key share in the market, which is attributed to increasing in the prevalence of diabetes majorly in Germany, Russia, and U.K (according to Diabetes UK 2016, about 3.6 Mn people are suffering from diabetes in the U.K. region), rise in the obese population due to change in lifestyle, increased R&D activities, and surge in demand for minimally invasive administration might propel the revenue growth of insulin market over the forecast years. Asia Pacific exhibiting significant growth owing to increase in diabetes population majorly in India and China (according to the International Diabetes Federation, in 2015, China around 96.2 million diabetic patients and India 66.8 million patients are suffering from diabetes.), rise in healthcare expenditure, and adoption of insulin in Asia Pacific region expected to bolster the insulin market.
Some of the players in Insulin market are Eli Lilly and Co. (U.S.), Merck & Co, Inc. (U.S.), Novo Nordisk A/S (Denmark), Sanofi (France), GlaxoSmithKline Plc. (U.K.). Biocon Ltd. (India), and Wockhardt Ltd. (India) to name a few.
In July 2017, Merck & Co. Inc. has received tentative approval from FDA for Lusduna Nexvue (insulin glargine) a biologic basal insulin to treat diabetes
In May 2017, Novo Nordisk A/S launched Xultophy 100/3.6 (insulin degludec/liraglutide) for type 2 diabetes patient
In January 2017, Sanofi launched Soliqua 100/33 (insulin glargine/lixisenatide) in the U.S. for the treatment of type 2 diabetes in adults
Global Market Outline: Insulin Market
Increase in the prevalence of diabetes, technological advancements in the insulin administration devices such as pen devices, change in the lifestyle leads to early onset of diabetes, the rise in the incidence of obesity, and favourable reimbursement policies expected to boost the insulin market over the forecast period. Moreover, product approval for insulin biosimilars in January 2016 by FDA for the Basaglar biosimilar in U.S, increase the awareness about the insulin usage, ease of administration, availability of the wider products, an upsurge in the demand for insulin analogues are anticipated propel the market over the forecast period. However, stringent regulatory policies for product approval, a high cost of the insulin, and manufacturing complexities might hamper the growth of insulin market over the forecast timeframe.
Global insulin market is segmented on the product type, diabetes type, and end user
Based on the product type, insulin market is segmented into the following:
Ultra-short acting insulin
Short-acting insulin
Intermediate-acting insulin
Long-acting insulin
Premixed insulin
Based on the diabetes type, insulin market is segmented into the following:
Type 1 diabetes
Type 2 diabetes
Based on the end user, insulin market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global insulin market is in the developed stage with several players operating in the market. Increase in the prevalence of diabetes and obesity, increase in the R&D activities for the development of insulin such as oral insulin and insulin patches is anticipated to propel the insulin market in the forthcoming years. Acquisitions & mergers, collaborations, product approval and launchings, and patent filings for the devices are some key strategies followed by the companies. For instance, in February 2016, Eli Lilly and Co. acquired Glycostasis, Inc. for the development of insulin. In addition, in August 2016, Emperra has launched Bluetooth enabled the insulin-delivering device in Germany.
Geographically, the insulin market is segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America anticipated to healthy growth rate owing to increase in the prevalence of diabetes in the U.S. (According to American Diabetes Association, the prevalence of diabetes in 2015 is 30.3 Mn or 9.4% in U.S.), a rise in the healthcare expenditure, and technological advancements in insulin administration. Europe holds a key share in the market, which is attributed to increasing in the prevalence of diabetes majorly in Germany, Russia, and U.K (according to Diabetes UK 2016, about 3.6 Mn people are suffering from diabetes in the U.K. region), rise in the obese population due to change in lifestyle, increased R&D activities, and surge in demand for minimally invasive administration might propel the revenue growth of insulin market over the forecast years. Asia Pacific exhibiting significant growth owing to increase in diabetes population majorly in India and China (according to the International Diabetes Federation, in 2015, China around 96.2 million diabetic patients and India 66.8 million patients are suffering from diabetes.), rise in healthcare expenditure, and adoption of insulin in Asia Pacific region expected to bolster the insulin market.
Some of the players in Insulin market are Eli Lilly and Co. (U.S.), Merck & Co, Inc. (U.S.), Novo Nordisk A/S (Denmark), Sanofi (France), GlaxoSmithKline Plc. (U.K.). Biocon Ltd. (India), and Wockhardt Ltd. (India) to name a few.
In July 2017, Merck & Co. Inc. has received tentative approval from FDA for Lusduna Nexvue (insulin glargine) a biologic basal insulin to treat diabetes
In May 2017, Novo Nordisk A/S launched Xultophy 100/3.6 (insulin degludec/liraglutide) for type 2 diabetes patient
In January 2017, Sanofi launched Soliqua 100/33 (insulin glargine/lixisenatide) in the U.S. for the treatment of type 2 diabetes in adults
1. EXECUTIVE SUMMARY
2. GLOBAL INSULIN MARKET INTRODUCTION
2.1. Global Insulin Market – Taxonomy
2.2. Global Insulin Market –Definitions
2.2.1. Product
2.2.2. Diabetes Type
2.2.3. End-User
3. GLOBAL INSULIN MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Insulin Market Dynamics – Factors Impact Analysis
3.6. Global Insulin Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INSULIN MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Ultra-short acting insulin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Short-acting insulin
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Intermediate-acting insulin
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Long-acting insulin
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Premixed insulin
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL INSULIN MARKET FORECAST, BY DIABETES TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Type 1 diabetes
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Type 2 diabetes
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL INSULIN MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL INSULIN MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User, and Region, 2017 – 2023
9. NORTH AMERICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Ultra-short acting insulin
9.1.2. Short-acting insulin
9.1.3. Intermediate-acting insulin
9.1.4. Long-acting insulin
9.1.5. Premixed insulin
9.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Type 1 diabetes
9.2.2. Type 2 diabetes
9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
9.6. North America Insulin Market Dynamics – Trends
10. EUROPE INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Ultra-short acting insulin
10.1.2. Short-acting insulin
10.1.3. Intermediate-acting insulin
10.1.4. Long-acting insulin
10.1.5. Premixed insulin
10.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Type 1 diabetes
10.2.2. Type 2 diabetes
10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
10.6. Europe Insulin Market Dynamics – Trends
11. ASIA-PACIFIC INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Ultra-short acting insulin
11.1.2. Short-acting insulin
11.1.3. Intermediate-acting insulin
11.1.4. Long-acting insulin
11.1.5. Premixed insulin
11.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Type 1 diabetes
11.2.2. Type 2 diabetes
11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
11.6. Asia- Pacific Insulin Market Dynamics – Trends
12. LATIN AMERICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Ultra-short acting insulin
12.1.2. Short-acting insulin
12.1.3. Intermediate-acting insulin
12.1.4. Long-acting insulin
12.1.5. Premixed insulin
12.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Type 1 diabetes
12.2.2. Type 2 diabetes
12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
12.6. Latin America Insulin Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Ultra-short acting insulin
13.1.2. Short-acting insulin
13.1.3. Intermediate-acting insulin
13.1.4. Long-acting insulin
13.1.5. Premixed insulin
13.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Type 1 diabetes
13.2.2. Type 2 diabetes
13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
13.6. MEA Insulin Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Eli Lilly and Co. (U.S.)
14.2.2. Merck & Co, Inc. (U.S.)
14.2.3. Novo Nordisk A/S (Denmark)
14.2.4. Sanofi (France)
14.2.5. GlaxoSmithKline Plc. (U.K.)
14.2.6. Biocon Ltd. (India)
14.2.7. Wockhardt Ltd. (India)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL INSULIN MARKET INTRODUCTION
2.1. Global Insulin Market – Taxonomy
2.2. Global Insulin Market –Definitions
2.2.1. Product
2.2.2. Diabetes Type
2.2.3. End-User
3. GLOBAL INSULIN MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Insulin Market Dynamics – Factors Impact Analysis
3.6. Global Insulin Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INSULIN MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Ultra-short acting insulin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Short-acting insulin
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Intermediate-acting insulin
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Long-acting insulin
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Premixed insulin
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL INSULIN MARKET FORECAST, BY DIABETES TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Type 1 diabetes
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Type 2 diabetes
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL INSULIN MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL INSULIN MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User, and Region, 2017 – 2023
9. NORTH AMERICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Ultra-short acting insulin
9.1.2. Short-acting insulin
9.1.3. Intermediate-acting insulin
9.1.4. Long-acting insulin
9.1.5. Premixed insulin
9.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Type 1 diabetes
9.2.2. Type 2 diabetes
9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
9.6. North America Insulin Market Dynamics – Trends
10. EUROPE INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Ultra-short acting insulin
10.1.2. Short-acting insulin
10.1.3. Intermediate-acting insulin
10.1.4. Long-acting insulin
10.1.5. Premixed insulin
10.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Type 1 diabetes
10.2.2. Type 2 diabetes
10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
10.6. Europe Insulin Market Dynamics – Trends
11. ASIA-PACIFIC INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Ultra-short acting insulin
11.1.2. Short-acting insulin
11.1.3. Intermediate-acting insulin
11.1.4. Long-acting insulin
11.1.5. Premixed insulin
11.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Type 1 diabetes
11.2.2. Type 2 diabetes
11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
11.6. Asia- Pacific Insulin Market Dynamics – Trends
12. LATIN AMERICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Ultra-short acting insulin
12.1.2. Short-acting insulin
12.1.3. Intermediate-acting insulin
12.1.4. Long-acting insulin
12.1.5. Premixed insulin
12.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Type 1 diabetes
12.2.2. Type 2 diabetes
12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
12.6. Latin America Insulin Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA INSULIN MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Ultra-short acting insulin
13.1.2. Short-acting insulin
13.1.3. Intermediate-acting insulin
13.1.4. Long-acting insulin
13.1.5. Premixed insulin
13.2. Diabetes Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Type 1 diabetes
13.2.2. Type 2 diabetes
13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Insulin Market - Opportunity Analysis Index, By Product, By Diabetes Type, By End-User and Country, 2017 – 2023
13.6. MEA Insulin Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Eli Lilly and Co. (U.S.)
14.2.2. Merck & Co, Inc. (U.S.)
14.2.3. Novo Nordisk A/S (Denmark)
14.2.4. Sanofi (France)
14.2.5. GlaxoSmithKline Plc. (U.K.)
14.2.6. Biocon Ltd. (India)
14.2.7. Wockhardt Ltd. (India)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
